---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-060715"
form_type: "8-K"
ticker: "LQDA"
cik: "0001819576"
company_name: "Liquidia Corp"
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:09:22.677592+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Liquidia Q1 net loss widens to $40.9M; YUTREPIA legal barriers removed

## Summary
- Net loss $40.9M ($0.54/share) vs $11.7M ($0.18) in Q1 2023; revenue fell 33% to $3.0M on lower Treprostinil Injection sales.
- Cash $157.9M after $100M gross proceeds from common stock private placement and RIFA fourth amendment in January 2024.
- G&A expenses surged 160% to $20.2M, driven by $3.1M higher litigation costs and $5.9M personnel rise.
- All legal barriers to FDA approval of YUTREPIA removed; awaiting ruling on preliminary injunction in new UTHR patent suit.
- ASCENT study of YUTREPIA in PH-ILD enrolling; L606 liposomal treprostinil data to be presented at ATS 2024.

## SEC filing metadata
- accession: 0001104659-24-060715
- form_type: 8-K
- ticker: LQDA
- cik: 0001819576
- company_name: Liquidia Corp
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819576/000110465924060715/0001104659-24-060715-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819576/000110465924060715/tm2414358d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-060715
- JSON: https://secwatch.observer/filing/0001104659-24-060715.json
- Plain text: https://secwatch.observer/filing/0001104659-24-060715.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.